156 related articles for article (PubMed ID: 34093844)
1. A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy.
Li Y; Tian M; Zhou Y; Tan F; Liu W; Zhao L; Perez D; Song X; Wang D; Nitschke C; Pei Q; Güngör C
J Cancer; 2021; 12(14):4433-4442. PubMed ID: 34093844
[No Abstract] [Full Text] [Related]
2. Effects of Total Pancreatectomy on Survival of Patients With Pancreatic Ductal Adenocarcinoma: A Population-Based Study.
Shao W; Lu Z; Xu J; Shi X; Tan T; Xing C; Song J
Front Surg; 2021; 8():804785. PubMed ID: 34957210
[No Abstract] [Full Text] [Related]
3. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.
Li G; Chen JZ; Chen S; Lin SZ; Pan W; Meng ZW; Cai XR; Chen YL
Cancer Med; 2020 May; 9(10):3353-3370. PubMed ID: 32181599
[TBL] [Abstract][Full Text] [Related]
4. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
5. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection.
Xie T; Wang X; Li M; Tong T; Yu X; Zhou Z
Eur Radiol; 2020 May; 30(5):2513-2524. PubMed ID: 32006171
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis.
Xu Y; Zhang Y; Han S; Jin D; Xu X; Kuang T; Wu W; Wang D; Lou W
Front Oncol; 2022; 12():789351. PubMed ID: 35433408
[TBL] [Abstract][Full Text] [Related]
8. Prognostic nomograms for gastric carcinoma after surgery to assist decision-making for postoperative treatment with chemotherapy cycles <9 or chemotherapy cycles ≥9.
Li Y; Zhang X
Front Surg; 2022; 9():916483. PubMed ID: 36090344
[TBL] [Abstract][Full Text] [Related]
9. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.
Shi J; Li X; Wu Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 50(3):375-382. PubMed ID: 34402250
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
[TBL] [Abstract][Full Text] [Related]
11. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy and its nomogram-based prediction.
Pu N; Yin H; Zhao G; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Cancer; 2019; 10(24):5935-5943. PubMed ID: 31762803
[No Abstract] [Full Text] [Related]
12. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
13. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features.
Moaven O; Clark CJ; Russell GB; Votanopoulos KI; Howerton R; Levine EA; Shen P
Ann Surg; 2021 Dec; 274(6):1058-1066. PubMed ID: 31913868
[TBL] [Abstract][Full Text] [Related]
14. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
15. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
[TBL] [Abstract][Full Text] [Related]
16. Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study.
Zhang Y; Xu G; Chen M; Wei Q; Zhou T; Chen Z; Shen M; Wang P
Front Oncol; 2020; 10():1018. PubMed ID: 32766130
[No Abstract] [Full Text] [Related]
17. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
18. The role of coeliac axis resection in resected ductal adenocarcinoma of the distal pancreas: A result of tumour topography or a prognostic factor?
Liu B; Wu J; Li C; Li Y; Qiu H; Lv A; Liu Q; Liu D; Wang Z; Hao C
Pancreatology; 2022 Jan; 22(1):112-122. PubMed ID: 34764022
[TBL] [Abstract][Full Text] [Related]
19. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy.
Habib JR; Kinny-Köster B; Bou-Samra P; Alsaad R; Sereni E; Javed AA; Ding D; Cameron JL; Lafaro KJ; Burns WR; He J; Yu J; Wolfgang CL; Burkhart RA
Ann Surg; 2023 Jan; 277(1):151-158. PubMed ID: 33843794
[TBL] [Abstract][Full Text] [Related]
20. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]